NovaBridge Biosciences (NBP)
NASDAQ: NBP · Real-Time Price · USD
3.990
+0.070 (1.79%)
At close: Dec 12, 2025, 4:00 PM EST
4.009
+0.019 (0.48%)
Pre-market: Dec 15, 2025, 8:45 AM EST
NovaBridge Biosciences Employees
NovaBridge Biosciences had 32 employees as of December 31, 2024. The number of employees decreased by 188 or -85.45% compared to the previous year.
Employees
32
Change (1Y)
-188
Growth (1Y)
-85.45%
Revenue / Employee
n/a
Profits / Employee
-$1,249,688
Market Cap
459.91M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32 | -188 | -85.45% |
| Dec 31, 2023 | 220 | -158 | -41.80% |
| Dec 31, 2021 | 378 | 150 | 65.79% |
| Dec 31, 2020 | 228 | 43 | 23.24% |
| Dec 31, 2019 | 185 | 51 | 38.06% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NBP News
- 4 days ago - NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO - GlobeNewsWire
- 11 days ago - NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO - GlobeNewsWire
- 24 days ago - NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward - GlobeNewsWire
- 6 weeks ago - NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries - GlobeNewsWire
- 6 weeks ago - I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform - GlobeNewsWire
- 7 weeks ago - I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025 - GlobeNewsWire
- 2 months ago - I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript - Seeking Alpha
- 2 months ago - I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences - GlobeNewsWire